# Determinants of response to cancer immunotherapy > **NIH NIH R35** · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2022 · $949,572 ## Abstract PROJECT SUMMARY/ABSTRACT While immunotherapy is transforming cancer treatment, the majority of patients do not achieve durable responses. We have been studying response and resistance to different immune checkpoint inhibitors and are now poised to propose mechanistic studies aimed at providing an understanding of the immune states and pathways that mediate or inhibit response to immune checkpoint blockade. Using high-dimensional unbiased single-cell RNA-seq (scRNAseq), we can identify both canonical and non-canonical immune effectors that can mediate anti-tumor responses. We believe that non-canonical effectors such as cytotoxic CD4 T cells, which we have recently described, are not effectively triggered by our current treatments. Using the same single-cell approaches, we can identify both known and novel cell types in cancer patients that can mediate immune suppression. In our first objective, we will determine whether combination immunotherapies that include drug(s) targeting specific immunosuppressive cells can enhance the function of these cytotoxic CD4+ T cells. By leveraging neoadjuvant clinical trials where patients receive immunotherapy prior to surgery, we will use single cell genomics and proteomics to define whether these combinations can 1) target the desired immunosuppressive mechanisms, and 2) enhance canonical and/or non-canonical effectors within the resected tumors. We will also use this approach to determine whether we can map these specific cell states into the circulating compartment. The second objective is based on a longstanding interest in our group to define the dynamics of antigen-specific responses. Using single-cell T cell receptor sequencing, we can identify expanded T cell clones as well as follow their localization. In addition to understanding how immunotherapy combinations induce and modulate specific T cell clonotypes within the tumor, we can determine how immunotherapies can induce functional plasticity to desired or undesired states. The third objective builds on our 20 year experience using mouse models to dissect mechanisms underlying response or resistance to immunotherapy. We will determine the functional significance of non-canonical immune effectors using depletion and knock-out strategies. We will also determine how combination immunotherapies can elicit both effective or ineffective anti- tumor immune responses, thereby guiding the design of future clinical trials. In conclusion, our proposal is based on hypothesis-driven bench-to-bedside and bedside-to-bench mechanistic studies with the goal of advancing cancer immunotherapy. With our deep expertise in this field, experience leading multi-disciplinary teams focused on translational research, and a rich network of basic science and clinical collaborators; we are uniquely positioned to succeed in the research plan outlined in this proposal. ## Key facts - **NIH application ID:** 10458030 - **Project number:** 5R35CA253175-02 - **Recipient organization:** UNIVERSITY OF CALIFORNIA, SAN FRANCISCO - **Principal Investigator:** Lawrence Fong - **Activity code:** R35 (R01, R21, SBIR, etc.) - **Funding institute:** NIH - **Fiscal year:** 2022 - **Award amount:** $949,572 - **Award type:** 5 - **Project period:** 2021-08-01 → 2028-07-31 ## Primary source NIH RePORTER: https://reporter.nih.gov/project-details/10458030 ## Citation > US National Institutes of Health, RePORTER application 10458030, Determinants of response to cancer immunotherapy (5R35CA253175-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10458030. Licensed CC0. --- *[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*